ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 153 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $15,400,031 | +13.0% | 1,485,056 | -11.9% | 0.07% | -1.5% |
Q1 2023 | $13,632,103 | -48.0% | 1,685,056 | +1.3% | 0.07% | -58.1% |
Q4 2022 | $26,202,881 | -19.2% | 1,663,675 | -19.3% | 0.16% | -22.7% |
Q3 2022 | $32,439,000 | +12.8% | 2,060,918 | 0.0% | 0.21% | +19.0% |
Q2 2022 | $28,770,000 | -19.0% | 2,060,918 | 0.0% | 0.17% | -5.9% |
Q1 2022 | $35,530,000 | +18.7% | 2,060,918 | +0.1% | 0.18% | +18.6% |
Q4 2021 | $29,932,000 | -15.0% | 2,058,618 | +5.3% | 0.16% | -18.3% |
Q3 2021 | $35,201,000 | +43.4% | 1,955,605 | +39.8% | 0.19% | +37.4% |
Q2 2021 | $24,555,000 | +85.3% | 1,398,372 | +165.9% | 0.14% | +67.5% |
Q1 2021 | $13,252,000 | – | 525,863 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |